Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2010 - 2025)

Rigel Pharmaceuticals' Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.0 million for Q3 2025.

• On a quarterly basis, Other Non-Current Liabilities changed 0.0% year-over-year to $5.0 million in Q3 2025; TTM through Sep 2025 was $5.0 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $5.0 million, down 87.48% from the prior year.
• Other Non-Current Liabilities held at $5.0 million in Q3 2025 per RIGL's latest filing, from $5.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $57.5 million in Q1 2021 and bottomed at $5.0 million in Q3 2024.
• The 5-year median for Other Non-Current Liabilities is $41.0 million (2023), against an average of $34.5 million.
• Across the five-year window, Other Non-Current Liabilities soared 1050.66% in 2021 and plunged 87.48% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $52.7 million in 2021, then declined by 19.84% to $42.3 million in 2022, then declined by 5.49% to $39.9 million in 2023, then plunged by 87.48% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
• Per Business Quant, the three latest RIGL Other Non-Current Liabilities figures stand at $5.0 million (Q3 2025), $5.0 million (Q2 2025), and $40.0 million (Q1 2025).